A EUR 30m loan granted by EIB to Mabion

European Investment Bank to fund the company’s development activity. The project is the first in Poland to benefit from the European Growth Finance Facility (EGFF) backed by the European Fund for Strategic Investments (EFSI) (the financial pillar of the Investment Plan for Europe – the Juncker Plan), which specialises in venture debt. The procured funds will be used to finance investment and R&D projects, including those related to the development of biosimilars and innovative biological medicines (used in cancer treatment), as well as to increase the company’s production capacities through the use of state-of-the-art research and development infrastructure.

“We are very pleased to have been able to support our client in procuring financing for the development of important research projects. The transaction was an innovative one – Poland’s first EGFF loan and one of the first venture debt financings. We would like to thank Mabion for our successful cooperation on the project” – commented Marcin Iwaniszyn, a partner and co-head of the banking and finance practice of Rymarz Zdort.

From the side of the Warsaw office, the transaction was supervised by Marcin Iwaniszyn, partner, and the team members included advocates Jerzy Bombczynski and Jakub Krzemien.

Mabion is a Polish biotech research company focused on the development and manufacture of medicines to treat certain types of blood cancer and rheumatoid arthritis.

The European Investment Bank is a lending institution of the European Union, whose shareholders are the member states of the EU. The Bank provides financing and guarantees to both public and private entities based in EU member states.